Ligand Pharmaceuticals Incorporated (LGNZZ) Financial Statements (2026 and earlier)

Company Profile

Business Address	3911 SORRENTO VALLEY BLVD SAN DIEGO, CA 92121
State of Incorp.	DE
Fiscal Year End	December 31
Industry (SIC)	2834 - Pharmaceutical Preparations (benchmarking)
More info	Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments	733,521	664,522	245,020	208,901	256,165	219,643
Cash and cash equivalent	174,927	139,376	67,669	47,989	72,307	63,619
Short-term investments	558,594	525,146	177,351	160,912	183,858	156,024
Restricted cash and investments
Receivables	61,047	58,096	42,116	42,831	42,449	42,131
Inventory, net of allowances, customer advances and progress billings	9,126	11,900	15,489	14,614	14,114	16,740
Inventory	9,126	11,900	15,489	14,614	14,114	16,740
Prepaid expense					1,934
Derivative instruments and hedges, assets						11,133
Asset, held-for-sale, not part of disposal group			35,228	29,685
Other current assets	5,785	6,986	4,816	13,285	16,897	19,741
Other undisclosed current assets	22,792	12,416	10,276
Total current assets:	832,271	753,920	352,945	309,316	331,559	309,388
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization					2,766	2,940
Operating lease, right-of-use asset		7,609	7,991	6,869	6,907	7,157
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization		3,466	3,632	3,623	15,133	15,094
Long-term investments and receivables	46,500	42,000				1,245
Long-term investments	46,500	42,000				1,245
Intangible asset, including goodwill, after accumulated amortization	326,979	335,076	351,674	359,932	371,898	380,155
Goodwill	101,541	101,541	101,541	101,541	105,250	105,250
Intangible asset, excluding goodwill, after accumulated amortization	225,438	233,535	250,133	258,391	266,648	274,905
Derivative instruments and hedges	15,632	9,351	17,958	18,029	10,583	19,246
Deferred income tax assets	8,345	9,526	829	546	72	78
Other noncurrent assets	12,582	2,771	9,111	7,892	6,924	8,404
Other undisclosed noncurrent assets	318,328	313,053	204,464	199,228	195,932	211,159
Total noncurrent assets:	728,366	722,852	595,659	596,119	610,215	645,478
TOTAL ASSETS:	1,560,637	1,476,772	948,604	905,435	941,774	954,866
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities	34,691	27,763	26,048	28,903	33,139	20,294
Accounts payable	3,238	3,679	8,584	5,366	5,233	4,694
Accrued liabilities	31,453	24,084	17,464	23,537	27,906	15,600
Deferred revenue			111	101	1,278	1,152
Debt	24		24	24	24	24
Other liabilities	135	135
Other undisclosed current liabilities	2,597	2,641	38,551	29,655	2,671	3,302
Total current liabilities:	37,447	30,539	64,734	58,683	37,112	24,772
Noncurrent Liabilities
Long-term debt and lease obligation	446,218	445,493			49
Long-term debt, excluding current maturities	446,192	445,493
Finance lease, liability	26				49
Liabilities, other than long-term debt	56,852	47,000	51,244	47,192	70,748	85,053
Deferred revenue					2,246	2,508
Deferred income tax liabilities	36,019	22,673	32,246	29,379	32,524	46,404
Other liabilities	16,629	19,912	14,369	14,248	30,163	29,874
Operating lease, liability	4,204	4,415	4,629	3,565	5,815	6,267
Other undisclosed noncurrent liabilities	2,908	3,569	4,097	4,026	3,426	3,863
Total noncurrent liabilities:	505,978	496,062	55,341	51,218	74,223	88,916
Total liabilities:	543,425	526,601	120,075	109,901	111,335	113,688
Equity
Equity, attributable to parent	1,017,212	950,171	828,529	795,534	830,439	841,178
Common stock	20	20	20	20	20	19
Additional paid in capital	400,649	362,614	358,635	340,544	337,377	309,341
Accumulated other comprehensive income (loss)	8,455	9,322	8,494	(1,563)	(5,942)	1,746
Retained earnings	608,088	578,215	461,380	456,533	498,984	530,072
Total equity:	1,017,212	950,171	828,529	795,534	830,439	841,178
TOTAL LIABILITIES AND EQUITY:	1,560,637	1,476,772	948,604	905,435	941,774	954,866

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Revenues	59,666	115,461	47,627	45,333	42,812	51,812
Cost of revenue (Cost of Product and Service Sold)	(8,096)	(8,097)	(2,907)	(8,257)		(100)
Gross profit:	51,570	107,364	44,720	37,076	42,812	51,712
Operating expenses	(45,823)	(60,530)	(39,183)	(81,549)	(52,449)	(48,669)
Other undisclosed operating income	8,096	8,097	2,907	8,257		100
Operating income (loss):	13,843	54,931	8,444	(36,216)	(9,637)	3,143
Nonoperating income (expense)	42,937	86,206	2,779	(13,964)	(29,563)	(9,482)
Investment income, nonoperating	28,456	11,672	2,560	(10,596)	(21,968)	3,754
Other nonoperating income (expense)	1,483	(443)	1,372	(2,501)	(6,712)	(12,495)
Interest and debt expense	(1,785)	(910)	(1,153)	(867)	(883)	(741)
Income (loss) from continuing operations before equity method investments, income taxes:	54,995	140,227	10,070	(51,047)	(40,083)	(7,080)
Other undisclosed income from continuing operations before income taxes	1,785	910	1,153	867	883	741
Income (loss) from continuing operations before income taxes:	56,780	141,137	11,223	(50,180)	(39,200)	(6,339)
Income tax expense (benefit)	(11,996)	(23,864)	(6,376)	7,729	8,112	(833)
Net income (loss) available to common stockholders, diluted:	44,784	117,273	4,847	(42,451)	(31,088)	(7,172)

Comprehensive Income ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Net income (loss):	44,784	117,273	4,847	(42,451)	(31,088)	(7,172)
Comprehensive income (loss):	44,784	117,273	4,847	(42,451)	(31,088)	(7,172)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent	(867)	828	10,057	4,379	(7,688)	2,681
Comprehensive income (loss), net of tax, attributable to parent:	43,917	118,101	14,904	(38,072)	(38,776)	(4,491)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Financial Reporting
and Analysis Software

Ligand Pharmaceuticals Incorporated (LGNZZ) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reportingand Analysis Software

Ligand Pharmaceuticals Incorporated (LGNZZ) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly

Income Statement (P&L) ($ in thousands)Annual | Quarterly

Comprehensive Income ($ in thousands)Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reporting
and Analysis Software

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly